Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

MS-DETECT: Tidlig påvisning af multipel skleroseprogression med MSCopilot® (MS-DETECT)

30. oktober 2026 opdateret af: Ad scientiam

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS).

The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution.

A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients.

Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL).

Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression.

The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

336

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Burnaby, Canada
        • Galina Vorobeychik
      • Ottawa, Canada
        • Mark Freedman
      • Toronto, Canada
        • St. Michael's Hospital
      • Vancouver, Canada
        • Robert Carruthers
      • Esbjerg, Danmark
        • University Hospital of Southern Denmark
      • Glostrup Municipality, Danmark
        • Finn Sellebjerg
      • Viborg, Danmark
        • Sivagini Prakash
    • California
      • San Diego, California, Forenede Stater, 92093
        • Jennifer Graves
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30327
        • Joash Lazarus Sr.
    • Illinois
      • Northbrook, Illinois, Forenede Stater, 60062
        • Daniel Wynn
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46256
        • Craig E. Herrman
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Jennifer Feng
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Robert Naismith
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43235
        • Aaron Boster
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Gabriel Pardo
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239-3098
        • Vijayshree Yadav
    • Texas
      • Austin, Texas, Forenede Stater, 78712
        • Leorah Freeman
      • Lille, Frankrig
        • Hôpital Roger Salengro
      • Lomme, Frankrig
        • Cécile Donzé
      • Marseille, Frankrig
        • Adil Maarouf
      • Nice, Frankrig
        • Mikael Cohen
      • Rouen, Frankrig
        • Bertrand Bourre
      • Florence, Italien
        • Emilio Portaccio
      • Foggia, Italien
        • Emanuele D'Amico
      • Milan, Italien
        • IRCCS Ospedale San Raffaele
      • Girona, Spanien
        • Gary Álvarez Bravo
      • Madrid, Spanien
        • University Hospital San Carlos
      • Madrid, Spanien
        • Enric Monreal
      • Málaga, Spanien
        • Ana Alonso
      • Oviedo, Spanien
        • Miguel Llaneza
      • Zaragoza, Spanien
        • Jesùs Martin
      • Bayreuth, Tyskland
        • Boris-Alexander Kallman
      • Dresden, Tyskland
        • Universitätsklinikum Carl Gustav Carus
      • Erbach im Odenwald, Tyskland
        • Rupert Knoblich

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

30 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adult patients living with RRMS or SPMS, aged 30 to 65
  • EDSS score between 2.5 to 6.5 points
  • With a disease duration > 5 years
  • Clinically stable during the last 3 months before inclusion (no relapses, no disability progression)
  • No change in the DMT* during the last 3 months before inclusion
  • Receiving optimal symptomatic treatments at baseline (clinician's judgment)
  • Owns a personal smartphone which mobile operating system is above 14 for IOS (iPhone) and 8 for Android included with a good internet connexion
  • Able to use a smartphone
  • Able to read language in wich the mobile application is available and able to understand pictograms.
  • Applicable to patients enrolled in France only: affiliated to a social security system.

Exclusion Criteria:

  • Medically unstable conditions that may hinder patient's ability to comply with the study procedures
  • Inability to use a smartphone or MSCopilot® Detect application
  • Patient with corrected visual acuity less than 4/10 (Monoyer) or 20/50 (Snellen at 20 feet) or +0,4 (LogMAR)
  • Pregnancy and nursing women
  • Persons under guardianship or curatorship
  • Current drugs or/and alcohol abuse that could influence performance on the tests (clinician's judgment)
  • Patients have participated in another clinical study within the previous 30 days of screening or are currently participating in another study that, in the opinion of the Investigator, might interfere with the patient's full participation in the study or confound the assessment of the patient or outcome of the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: MSCopilot® Detect

Performance of digital tests and standard test in clinic at D0, M6, M12, M18 and M24 (if applicable) Use of MSCopilot® Detect at-home in between visits during 18 or 24 months (if applicable)

MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on revised-MSFC scores.
Tidsramme: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The discriminatory ability of the MSCopilot® Detect application in detecting clinically meaningful worsening (disability worsening) based on the revised-MSFC will be evaluated using the Area Under the ROC Curve (AUC) method. Confidence intervals will also be estimated.

The minimum significant AUC value will be set at >0.67, and Confidence Intervals will be calculated. Sensitivity and specificity will also be determined. To validate the estimated AUC values and cutoffs generated by the MSCopilot® Detect application, a train/test set will be utilised.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on EDSS.
Tidsramme: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The study will evaluate the sensitivity, specificity, concordance, and accuracy of the MSCopilot® Detect application in predicting confirmed disability worsening (CDW) at 24 weeks as also captured by the EDSS, using a contingency table.

We will also generate time series box plots of MSCopilot® Detect individual scores and/or composite scores based on the patient progression status (determined by EDSS), using both intra-patient and inter-patient visualisation.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening earlier than the EDSS.
Tidsramme: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The time to progression-free events based on EDSS and MSCopilot® Detect individual scores and/or composite scores will be estimated with a Kaplan-Meier method (Log-rank test for comparison). Univariate and multivariate survival models (e.g. Cox or Anderson-Gill survival model), will be used to estimate Hazards Rates (HRs), if relevant.

Proportions of disability worsening based on MSCopilot® Detect composite or individual scores and worsening based on the EDSS 24-week CDW will be compared for each timepoint.

Time series boxplot of MSCopilot® Detect individual scores and/or composite score according to the patient disability worsening (by EDSS) intra-patient and inter-patient.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect individual and/or composite scores ability to detect disease progression in absence of a relapsing activity (PIRA).
Tidsramme: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

Proportion of patients with PIRA (progression independent of relapses) based either on EDSS 24-week CDP compared to the proportion of patients with PIRA based on MSCopilot® Detect composite or individual scores progression status.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect individual scores and/or composite scores ability to detect MSFC changes over time.
Tidsramme: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

Slopes parameters will be computed using a mix model to characterize the change from baseline in MSCopilot® Detect individual and/or composite scores and revised-MSFC scores over time.

The association between these slopes parameters will be assessed using correlation coefficient.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To measure MSCopilot® Detect individual scores and/or composite scores association with the clinical scores.
Tidsramme: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The association between digital and clinical scores will be studied with correlation coefficient calculated between:

  • MSCopilot® Detect individual scores ((MWPT, MDT, MCT, MVT and Mobile Walking Endurance Test (MWET)) and/or composite score at home and EDSS score performed in clinic.
  • MSCopilot® Detect individual scores (MWPT, MDT, MCT, MVT and MWET) and/or composite score at home and revised-MSFC-3 or Revised-MSFC3 + SLCLAT scores performed in clinic.
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To assess reproducibility of MSCopilot® Detect individual scores and/or composite scores between in-clinic and at-home digital tests.
Tidsramme: At home (Day 1, Month 6+1 day, Month 12 + 1 day, Month 18-1 day and Month 24-1 day (if applicable)) and in-clinic ((Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable))

Intraclass correlation coefficient (ICC) between MSCopilot® Detect individual scores and/or composite score at home and in-clinic.

At home (Day 1, Month 6+1 day, Month 12 + 1 day, Month 18-1 day and Month 24-1 day (if applicable)) and in-clinic ((Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable))
To assess reliability of MSCopilot® Detect individual scores and/or composite scores at-home over time.
Tidsramme: Day 0 versus Month 6, Month 6 versus Month 12, Month 12 versus Month 18, Month18 versus Month 24 (if applicable) AND Day 0 to Month 18 or Day 0 to Month 24 (if applicable) and Day 0 to Month 15 or Day 0 to Month 21 (if applicable) at home.

Intraclass correlation coefficient (ICC) of MSCopilot® Detect individual scores and/or composite score at home with a maximum paired time point of 6 months.

ICC of MSCopilot® Detect individual scores and/or composite score at home will over time.

Day 0 versus Month 6, Month 6 versus Month 12, Month 12 versus Month 18, Month18 versus Month 24 (if applicable) AND Day 0 to Month 18 or Day 0 to Month 24 (if applicable) and Day 0 to Month 15 or Day 0 to Month 21 (if applicable) at home.
To evaluate Patient QoL (Multiple Sclerosis Impact Scale: MSIS-29 and Modified Fatigue Impact Scale - 5-item version: MFIS-5) and their association with MSCopilot® Detect individual and composite scores.
Tidsramme: Throughout the study between in clinic visit, an average of 24 months

Analysis of MSIS-29 and MFIS-5 questionnaires:

Descriptive analysis of questionnaire scores over time. Comparison of Patient QoL between patients with and without a confirmed disability worsening Correlation between MSCopilot® Detect individual and/or composite score at home and Questionnaires scores (MSIS29 and MFIS-5).

Sensitivity, specificity, concordance, and accuracy will be evaluated between clinically meaningful change of MSCopilot® Detect application (individual and composite scores) and questionnaires (MSIS29 and MFIS-5).

Proportions comparison of patients with a clinically meaningful change will be assessed between MSCopilot® Detect application (individual and composite scores) and questionnaires (MSIS29 and MFIS-5).

Clinically meaningful change for questionnaires:

MSIS-29: 8-point change compared to baseline. MFIS-5: 4-point change compared to baseline.

Throughout the study between in clinic visit, an average of 24 months
To evaluate the ability of MSCopilot® Detect individual scores and/or composite score to discriminate between a relapse and a momentary disability worsening (+1 point EDSS score for an initial EDSS <5,5; +0.5 point for an initial EDSS ≥5.5).
Tidsramme: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

Descriptive analysis:

MSCopilot® Detect individual and/or composite score profiles, between relapse and a momentary disability worsening patient.

Annualized Relapse Rate (ARR) calculation. Logistic regression to estimate Area under ROC Curve (i.e. discriminatory power).

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect Safety
Tidsramme: Throughout the study between in clinic visit, an average of 24 months

Descriptive analysis of the number of Adverse Events related to MSCopilot® Detect will be reported.

Throughout the study between in clinic visit, an average of 24 months
To evaluate MSCopilot® Detect Adherence
Tidsramme: Throughout the study between in clinic visit, an average of 24 months

Descriptive analysis of the mobile application's adherence data (number of completed questionnaires, number of performed tests, number of performed sessions, etc.)

Throughout the study between in clinic visit, an average of 24 months
To assess the satisfaction and user experience with the MSCopilot® Detect smartphone application and the MSCopilot® Detect web dashboard.
Tidsramme: Every 3 months for about 24 months

Descriptive analysis over the course of the study of the answers to the patient satisfaction and user experience questionnaires related to the use of the MSCopilot® Detect smartphone application.

Every 3 months for about 24 months
To assess the satisfaction and user experience with the MSCopilot® Detect web dashboard.
Tidsramme: Every 6 months for about 24 months

Descriptive analysis over the course of the study of the answers to physician satisfaction & user experience questionnaires relative to the use of the MSCopilot® Detect web dashboard.

Every 6 months for about 24 months
To describe the evolution of MSCopilot® Detect individual scores and/or composite scores at-home over time.
Tidsramme: Throughout the study between in clinic visit, an average of 24 months

The time to progression-free events based on MSCopilot® Detect individual scores and/or composite scores will be estimated with a Kaplan-Meier method (Log-rank test for comparison). Univariate and multivariate survival models (e.g. Cox or Anderson-Gill survival model), will be used to estimate Hazards Rates (HRs), if relevant.

Cumulative proportions of disability worsening based on MSCopilot® Detect composite or individual scores for each timepoint.

Time series boxplot of MSCopilot® Detect individual scores and/or composite score according to the patient disability worsening (by MSCopilot® Detect) using both intra-patient and inter-patient visualisation.

Throughout the study between in clinic visit, an average of 24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. september 2023

Primær færdiggørelse (Anslået)

31. maj 2027

Studieafslutning (Anslået)

31. maj 2027

Datoer for studieregistrering

Først indsendt

13. marts 2023

Først indsendt, der opfyldte QC-kriterier

3. april 2023

Først opslået (Faktiske)

18. april 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner